Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1247-1252

  Karlowsky, James A ^a,b   Walkty, Andrew J ^a,b   Adam, Heather J ^a,b   Baxter, Melanie R ^a   Hoban, Daryl J ^a,b   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOXITIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; BROTH DILUTION; CANADA; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARABACTEROIDES DISTASONIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; CANADA; CLINDAMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 84857150041     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05823-11     Document Type: Article

References (18)

1. Bourgault A-M, et al. 1986. Survey of anaerobic susceptibility patterns in Canada. Antimicrob. Agents Chemother. 30:798-801. (Pubitemid 17187719)
2. Bourgault A-M, et al. 1992. Survey of Bacteroides fragilis group susceptibility patterns in Canada. Antimicrob. Agents Chemother. 36:343-347.
3. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, seventh edition, M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement, vol. 31, no. 1. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cuchural GR, Jr, et al. 1988. Susceptibility of Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob. Agents Chemother. 32:717-722.
6. Goldstein EJC, Citron DM. 2011. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I. Clin. Microbiol. Newsl. 33:1-8.
7. Goldstein EJC, Citron DM. 2011. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part II. Clin. Microbiol. Newsl. 33:9-15.
8. Goldstein EJC, Citron DM, Goldman PJ, Goldman RJ. 2008. National hospital survey of anaerobic culture and susceptibility methods: III. Anaerobe 14:68-72.
9. Johnson JL. 1978. Taxonomy of Bacteroides. I. Deoxyribonucleic acid homologies among Bacteroides fragilis and other saccharoclastic Bacteroides species. Int. J. Syst. Bacteriol. 28:245-256. (Pubitemid 8322495)
10. Liu C-Y, et al. 2008. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob. Agents Chemother. 52:3161-3168.
11. Livermore DM. 2009. Doripenem: antimicrobial profile and clinical potential. Diagn. Microbiol. Infect. Dis. 63:455-458.
12. National Committee for Clinical Laboratory Standards. 2002. Abbreviated identification of bacteria and yeast; approved guideline, M35-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Nguyen MH, et al. 2000. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: finding of a multicenter prospective observational trial. Clin. Infect. Dis. 30:870-876.
14. Roh KH, et al. 2010. New cfiA variant and novel insertion sequence elements in carbapenem-resistant Bacteroides fragilis isolates from Korea. Diagn. Microbiol. Infect. Dis. 66:343-348.
15. Snydman DR, et al. 2011. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 17:147-151.
16. Snydman DR, et al. 2010. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin. Infect. Dis. 50(Suppl. 1):S26-S33.
17. Snydman DR, et al. 2007. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents Chemother. 51:1649-1655. (Pubitemid 46744140)
18. Sóki J, et al. 2004. Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides isolates from the USA, Hungary and Kuwait. J. Med. Microbiol. 53:413-419. (Pubitemid 38586508)